Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1517"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1126"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:content	"7.5 Drugs metabolized by CYP2C19 In a clinical study in Japan evaluating rabeprazole in patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied."
dc:creator	"boycer"
dc:date	"09/24/2009 13:53:17"
rdfs:seeAlso	?:5d103551-978f-472a-9c62-51e6e4dea068

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ rabeprazole_substrate_of_cyp2c19, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1126 }

Context graph